1. Home
  2. BCYC vs BGY Comparison

BCYC vs BGY Comparison

Compare BCYC & BGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCYC
  • BGY
  • Stock Information
  • Founded
  • BCYC 2009
  • BGY 2007
  • Country
  • BCYC United Kingdom
  • BGY United States
  • Employees
  • BCYC N/A
  • BGY N/A
  • Industry
  • BCYC Biotechnology: Pharmaceutical Preparations
  • BGY Trusts Except Educational Religious and Charitable
  • Sector
  • BCYC Health Care
  • BGY Finance
  • Exchange
  • BCYC Nasdaq
  • BGY Nasdaq
  • Market Cap
  • BCYC 566.5M
  • BGY 487.0M
  • IPO Year
  • BCYC 2019
  • BGY N/A
  • Fundamental
  • Price
  • BCYC $7.44
  • BGY $5.80
  • Analyst Decision
  • BCYC Buy
  • BGY
  • Analyst Count
  • BCYC 10
  • BGY 0
  • Target Price
  • BCYC $25.00
  • BGY N/A
  • AVG Volume (30 Days)
  • BCYC 274.8K
  • BGY 208.4K
  • Earning Date
  • BCYC 08-05-2025
  • BGY 01-01-0001
  • Dividend Yield
  • BCYC N/A
  • BGY 7.41%
  • EPS Growth
  • BCYC N/A
  • BGY N/A
  • EPS
  • BCYC N/A
  • BGY N/A
  • Revenue
  • BCYC $25,722,000.00
  • BGY N/A
  • Revenue This Year
  • BCYC $7.35
  • BGY N/A
  • Revenue Next Year
  • BCYC N/A
  • BGY N/A
  • P/E Ratio
  • BCYC N/A
  • BGY N/A
  • Revenue Growth
  • BCYC N/A
  • BGY N/A
  • 52 Week Low
  • BCYC $6.10
  • BGY $4.68
  • 52 Week High
  • BCYC $28.67
  • BGY $5.66
  • Technical
  • Relative Strength Index (RSI)
  • BCYC 44.12
  • BGY 55.87
  • Support Level
  • BCYC $6.87
  • BGY $5.68
  • Resistance Level
  • BCYC $7.59
  • BGY $5.78
  • Average True Range (ATR)
  • BCYC 0.46
  • BGY 0.06
  • MACD
  • BCYC -0.06
  • BGY 0.00
  • Stochastic Oscillator
  • BCYC 29.69
  • BGY 73.33

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

About BGY Blackrock Enhanced International Dividend Trust

Blackrock Enhanced International Dividend Trust has an investment objective to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its objectives by investing in equity securities of companies engaged in the energy and natural resources business and equity derivatives with exposure to the energy and natural resources industry.

Share on Social Networks: